BioNTech is a biotechnology company based in Germany that focuses on developing and manufacturing immunotherapies for cancer and other serious diseases. It is particularly well-known for its role in the development of one of the first mRNA COVID-19 vaccines, developed in collaboration with Pfizer. The company’s innovative approach uses messenger RNA (mRNA) technology to instruct cells to produce proteins that can trigger an immune response against specific diseases. BioNTech’s work extends beyond vaccines, as it explores various therapeutic areas, including personalized cancer treatments and infectious disease vaccines.
BioNTech přechází od vakcín proti COVID-19 k terapiím rakoviny založeným na mRNA, což ovlivňuje finanční dynamiku. Přestože došlo k poklesu zisků v roce 2024, BioNTech překonal očekávání trhu s €1,08…